Publication | Open Access

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

First-line TherapyOncologyOverall SurvivalMetronomic TherapyClinical TrialsBronchial NeoplasmCancer TreatmentMedicineRadiation OncologyLung CancerHealth Sciences